Selected Abstracts from the EASL Conference – April 14-18, 2004 Berlin, German

Hepatitis B

HBV Treatment

Current Therapies-

• Adefovir
• Durability of HBeAg Seroconversion after Adefovir Dipivoxil Treatment for Chronic Hepatitis B
• Long-Term Incidence of Adefovir Dipivoxil Resistance in Chronic Hepatitis B Patients after 144 Weeks of Therapy
• Three Year Study of Adefovir Dipivoxil Demonstrates Sustained Efficacy in Presumed Precore Mutant Chronic Hepatitis B Patients in A Long Term Safety and Efficacy Study

Diagnostic Tools –

• Evaluation of the RealQuant HBV-DNA Assay (Realtime PCR)
• Models to Predict Inflammation and Fibrosis in Patients with Chronic Hepatitis B

Disease Progression –

• Models to Predict Inflammation and Fibrosis in Patients with Chronic Hepatitis B

Experimental Therapies–

• Entecavir
• Absence of Entecavir Resistance Emergence in Lamivudine-Refractory Patients for at Least One Year With Entecavir Study AI463-014
• Lamivudine-Refractory Hepatitis B Patients Can Be Safely Switched Directly to Entecavir 1 MG Daily Therapy
• Hepavir B
• Development of Hepavir B, a Prodrug of PMEA with Excellent Liver-Targeting Properties
• Interferon based therapies
• Pegasys
• Peginterferon Alfa-2A (40KD) (Pegasys) Monotherapy is More Effective Than Lamivudine Monotherapy in the Treatment of HBEAG-Negative Chronic Hepatitis B: 72 Week Results From a Phase III, Partially Double-Blind Study of Pegasys Alone vs. Pegasys Plus Lamivudine vs. Lamivudine
• Peg-Intron
• A randomized trial of peginterferon alfa-2b and lamivudine combination treatment versus lamivudine monotherapy in chinese patients with hbeag-positive chronic hepatitis b
• Liver histology in chronic hepatitis b patients after 1 year of treatment with pegylated interferon alpha-2b in combination with lamivudine or placebo
• Viral dynamics during peg-interferon alone and in combination with lamivudine
• Standard Interferon
• Interferon Plus Lamivudine vs. Lamivudine Monotherapy in Patients with Chronic Hepatitis B Anti-HBe Positive
• LDT
• Results of a One-Year International Phase IIB Trial of LDT, and LDT, Plus Lamivudine, In Patients With Chronic Hepatitis B
• Pediatrics
• The Pharmacokinetics (PK) and Safety of A Single Dose of Adefovir Dipivoxil in Children and Adolescents (Aged 2-17) with Chronic Hepatitis B
• A Prospective Open Study of Long-Term Lamivudine Treatment in Children with Chronic Hepatitis B Unresponsive to Previous In To Previous Interferon Alpha Therapy

Genotype–

• Multi-Center Study of Hepatitis B Virus (HBV) Genotypes in France: Geographic Distribution, Correlation with HBeAg-Positive Status and Relation to Liver Fibrosis
• Hepatitis B Virus Genotype Mixtures: Clinical Relevance and Molecular Characteristics

Occult HBV–

• HBV Genomes From Liver Tissue of Patients With Occult HBV Infection Show Wide Range of Sequence Divergence and Normally Replicate In Vivo

Transmission–

• Paired Measurement of Quantitative Hepatitis B Virus DNA in Saliva, Urine and Serum of Chronic Hepatitis B Patients

Treatment–

• The Immunomodulatory Effect of Steroids in Chronic Hepatitis B
• The Long-Term Outcome of HBeAg-Negative Patients With Cirrhosis Treated With Lamivudine Monotherapy: A 5-Year Prospective Cohort Study
• Lowest Serum Hepatitis B Virus DNA Level is Predictable Factor for Viral Breakthrough During Lamivudine Therapy in Chronic Hepatitis B Patients

Viral Kinetics–

• A New Bio-Mathematical Model to Describe the Dynamics of HBV-DNA and Infected Hepatocytes in HBEAG-Negative/Anti-HBE-Positive Chronic Hepatitis B Patients Treated with Peginterferon Alfa-2A (40KD) (Pegasys), Lamivudine, or Pegasys Plus Lamivudine Combination Therapy